PMID- 37514031
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 7
DP  - 2023 Jun 28
TI  - Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck 
      Squamous Cell Carcinomas.
LID - 10.3390/pharmaceutics15071844 [doi]
LID - 1844
AB  - Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers 
      in the world, with surgery, radiotherapy, chemotherapy, and immunotherapy being 
      the primary treatment modalities. The treatment for HNSCC has evolved over time, 
      due to which the prognosis has improved drastically. Despite the varied treatment 
      options, major challenges persist. HNSCC chemotherapeutic and immunotherapeutic 
      drugs are usually administered systemically, which could affect the patient's 
      quality of life due to the associated side effects. Moreover, the systemic 
      administration of salivary stimulating agents for the treatment of 
      radiation-induced xerostomia is associated with toxicities. Localized drug 
      delivery systems (LDDS) are gaining importance, as they have the potential to 
      provide non-invasive, patient-friendly alternatives to cancer therapy with 
      reduced dose-limiting toxicities. LDDSs involve directly delivering a drug to the 
      tissue or organ affected by the disease. Some of the common localized routes of 
      administration include the transdermal and transmucosal drug delivery system 
      (DDSs). This review will attempt to explore the different treatment options using 
      LDDSs for the treatment of HNSCC and radiotherapy-induced damage and their 
      potential to provide a better experience for patients, as well as the obstacles 
      that need to be addressed to render them successful.
FAU - Hariharan, Arvind
AU  - Hariharan A
AUID- ORCID: 0000-0003-2204-2618
AD  - McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of 
      Dental Medicine and Oral Health Sciences, McGill University, 3640 University 
      Street, Montreal, QC H3A 0C7, Canada.
FAU - Tran, Simon D
AU  - Tran SD
AUID- ORCID: 0000-0001-5594-359X
AD  - McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of 
      Dental Medicine and Oral Health Sciences, McGill University, 3640 University 
      Street, Montreal, QC H3A 0C7, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230628
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC10385385
OTO - NOTNLM
OT  - head and neck squamous cell carcinoma
OT  - localized drug delivery
OT  - nanoparticles
OT  - penetration enhancers
OT  - transdermal
OT  - transmucosal
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:44
MHDA- 2023/07/29 11:45
PMCR- 2023/06/28
CRDT- 2023/07/29 01:39
PHST- 2023/04/13 00:00 [received]
PHST- 2023/06/12 00:00 [revised]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/07/29 11:45 [medline]
PHST- 2023/07/29 11:44 [pubmed]
PHST- 2023/07/29 01:39 [entrez]
PHST- 2023/06/28 00:00 [pmc-release]
AID - pharmaceutics15071844 [pii]
AID - pharmaceutics-15-01844 [pii]
AID - 10.3390/pharmaceutics15071844 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Jun 28;15(7):1844. doi: 10.3390/pharmaceutics15071844.